During the last session, Revolution Medicines Inc. (NASDAQ:RVMD)’s traded shares were 1.49 million. At the end of the trading day, the stock’s price was $18.15, reflecting an intraday loss of -0.22% or -$0.04. The 52-week high for the RVMD share is $34.66, that puts it down -90.96 from that peak though still a striking 22.42% gain since the share price plummeted to a 52-week low of $14.08. The company’s market capitalization is $1.26B, and the average intraday trading volume over the past 10 days was 1.08 million shares, and the average trade volume was 750.94K shares over the past three months.
Revolution Medicines Inc. (NASDAQ:RVMD) trade information
Revolution Medicines Inc. (RVMD) registered a -0.22% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.22% in intraday trading to $18.15 this Wednesday, 06/22/22, hitting a weekly high. The stock’s 5-day price performance is 7.97%, and it has moved by 15.38% in 30 days. Based on these gigs, the overall price performance for the year is -44.88%. The short interest in Revolution Medicines Inc. (NASDAQ:RVMD) is 9.3 million shares and it means that shorts have 13.28 day(s) to cover.
Revolution Medicines Inc. (RVMD) estimates and forecasts
Statistics show that Revolution Medicines Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Revolution Medicines Inc. (RVMD) shares have gone down -29.76% during the last six months, with a year-to-date growth rate less than the industry average at -39.30% against 11.30. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -40.00% this quarter and then drop -26.40% in the quarter after that. In the rating firms’ projections, revenue will increase 2.70% compared to the previous financial year.
Revenue for the current quarter is expected to be $7.02 million as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to $5.97 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $8.7 million and $1.1 million respectively. In this case, analysts expect current quarter sales to shrink by -19.30% and then jump by 442.20% in the coming quarter.
While earnings are projected to return -27.80% in 2022.
Revolution Medicines Inc. is due to release its next quarterly earnings between August 09 and August 15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Revolution Medicines Inc. (NASDAQ:RVMD)’s Major holders
Revolution Medicines Inc. insiders own 1.70% of total outstanding shares while institutional holders control 100.81%, with the float percentage being 102.55%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 211 institutions own stock in it. As of Mar 30, 2022, the company held over 6.06 million shares (or 8.16% of all shares), a total value of $154.54 million in shares.
The next largest institutional holding, with 5.52 million shares, is of TRV GP III, LLC’s that is approximately 7.44% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $140.92 million.
Also, the Mutual Funds coming in first place with the largest holdings of Revolution Medicines Inc. (RVMD) shares are Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 1.96 million shares. This amounts to just over 2.64 percent of the company’s overall shares, with a $49.99 million market value. The same data shows that the other fund manager holds slightly less at 1.66 million, or about 2.24% of the stock, which is worth about $33.23 million.